UC Irvine Medical Center SC
Welcome,         Profile    Billing    Logout  
 2 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fruehauf, John
IGNYTE, NCT03767348 / 2016-004548-12: Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Hourglass Jan 2024 - Mar 2024 : Data from IGNYTE trial in combination with Opdivo for 2L melanoma
Checkmark From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Nov 2020 - Nov 2020: From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Checkmark Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Nov 2019 - Nov 2019: Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Recruiting
2
340
Europe, US
RP1, nivolumab, Opdivo
Replimune Inc., Bristol-Myers Squibb
Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
12/25
12/28
Jones, Rebecca
NCT06605703: A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)

Recruiting
4
225
US
WW Clinic, Bupropion-Naltrexone, Bupropion-Naltrexone-Metformin
Michelle Cardel, PhD, MS, RD
Obesity, Overweight
05/25
08/25
NCT06453213: Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy

Recruiting
4
90
US
Cenobamate
SK Life Science, Inc.
Focal Onset Seizure
05/27
07/27
Meds WOW-WW, NCT06470659: Medications with or Without WeightWatchers

Active, not recruiting
N/A
101
US
WW Clinic
Michelle Cardel, PhD, MS, RD
Obesity, Overweight
01/25
02/25

Download Options